Moderna is asking for the green light from regulators to grant it vaccine in adolescents over 12 years of age in the EU, USA and Canada while Pfizer, whose vaccine is already given at these ages, is planning clinical trials in younger children. Novavax will begin testing its vaccine in children in July, while China has already approved the Sinovac vaccine for emergency use in children over 3 years of age, according to the APE.
Countries that have approved or plan to approve the vaccination of children:
European Union
Denmark will vaccinate children aged 12 to 15, TV2 reported on June 17, citing official sources.
France has started vaccinating children aged 12 and over, subject to parental consent.
The German Vaccine Advisory Committee recommended on June 10 that only children and adolescents with underlying health problems should be vaccinated with the Pfizer vaccine.
Austria plans to vaccinate 340,000 children aged 12-15 by the end of August, according to the news site Vindobona.
Estonia plans to start vaccinating teenagers in the autumn, according to the head of the governing council for the management of the Covid-19 epidemic.
Hungary began vaccinating children aged 16 to 18 in mid-May.
Italy approved on May 31 the extension of its vaccination program to children aged 12-15.
The Prime Minister of Lithuania announced the start of vaccination of children over 12 in June.
Spain plans to start vaccinating 12- to 17-year-olds about two weeks before the start of the next school year.
The Netherlands will offer the Pfizer-BioNTech vaccine against COVID-19 to all children aged 12 to 17 in an effort to prevent a new wave of outbreaks of coronavirus strains in the coming months.
Europe (outside the EU)
The British Vaccination Committee will not make a decision on vaccinating teens before July, although the UK regulator has approved the Pfizer-BioNTech vaccine for 12- to 15-year-olds.
Switzerland approved the vaccination of children aged 12 to 15 years with the Pfizer vaccine on 4 June.
Norway may consider using the Pfizer vaccine for children at high risk of serious illness from COVID-19.
San Marino started vaccinations for children aged 12-15.
Middle East
Israel has launched a vaccination campaign for children aged 12-15, as the Delta variant of the virus has launched a number of cases.
Dubai is offering the Pfizer-BioNTech vaccine to children aged 12 to 15, after the United Arab Emirates approved its emergency use for this age group in mid-May.
Asia – Southeast Asia
Indonesia recommended vaccinating the 12-17 team on June 28 and the campaign will begin soon.
New Zealand regulator has approved the use of the Pfizer-BioNTech vaccine for the 12-15 age group, Prime Minister Jacinda Arden announced on June 21.
China on June 5 approved the urgent use of the Sinovac vaccine for ages 3 to 17.
Hong Kong announced on June 3 that it intends to open a vaccination platform for children over 12 years of age.
Singapore launched the vaccination platform for 12-18 year olds on June 1.
Japan on May 28 approved the use of the Pfizer-BioNTech vaccine for people 12 years of age and older.
The Philippines on May 26 decided to allow the use of the Pfizer-BioNTech vaccine in children aged 12-15 years.
America
Mexico on June 24 approved the Pfizer-BioNTech vaccine for use in children 12 years and older.
Brazil on June 11 approved the use of the Pfizer vaccine for children over 12 years of age.
Chile has approved the use of the Pfizer vaccine for children aged 12 to 16 years.
The United States began vaccinating young people and adolescents in mid-May.
Canada approved the use of the Pfizer vaccine in children aged 12-15 in early May.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
